respiratori
virus
infect
caus
influenza
virus
human
parainfluenza
viru
hpiv
respiratori
syncyti
viru
rsv
coronavirus
emin
threat
public
health
current
licens
vaccin
avail
hpiv
rsv
coronavirus
avail
season
influenza
vaccin
consider
limit
regard
pandem
prepared
import
procedur
place
respond
rapidli
produc
tailor
made
vaccin
respiratori
virus
short
notic
moreov
especi
influenza
great
need
develop
univers
vaccin
induc
broad
protect
immun
influenza
virus
variou
subtyp
modifi
vaccinia
viru
ankara
mva
replicationdefici
viral
vector
hold
great
promis
vaccin
platform
mva
encod
one
foreign
antigen
thu
function
multival
vaccin
vector
use
biosafeti
level
intrins
adjuv
capac
induc
humor
cellular
immun
respons
howev
practic
regulatori
issu
need
virus
address
order
develop
mvabas
vaccin
short
notic
verg
pandem
review
discuss
promis
novel
influenza
viru
vaccin
target
use
mva
vaccin
develop
variou
respiratori
virus
respiratori
virus
season
pandem
influenza
virus
human
parainfluenza
viru
hpiv
respiratori
syncyti
viru
rsv
coronavirus
caus
substanti
burden
diseas
global
pathogen
caus
respiratori
tract
infect
mainli
young
children
elderli
immunocompromis
individu
contrast
season
influenza
current
licens
rsv
hpiv
vaccin
avail
influenza
recommend
annual
vaccin
peopl
risk
protect
infect
season
influenza
virus
howev
result
select
pressur
exert
virusspecif
antibodi
induc
previou
infect
andor
vaccin
season
influenza
virus
accumul
mutat
antigen
site
two
main
surfac
protein
hemagglutinin
ha
neuraminidas
na
consequ
antigen
drift
variant
emerg
evad
host
immun
occasion
avian
swine
influenza
virus
introduc
human
popul
sinc
neutral
antibodi
novel
virus
virtual
absent
human
popul
larg
suscept
infect
last
year
alon
sever
avian
influenza
virus
caus
human
infect
februari
februari
human
case
infect
virus
display
sign
adapt
human
report
one
hundr
twelv
case
fatal
outcom
although
sustain
humantohuman
transmiss
virus
report
possibl
acquir
abil
mutat
shown
experiment
virus
ferret
addit
human
case
infect
avian
virus
subtyp
report
fatal
outcom
one
virus
becom
transmiss
humantohuman
caus
widespread
outbreak
could
evolv
influenza
pandem
consider
morbid
mortal
term
pandem
prepared
procedur
place
respond
rapidli
produc
tailor
made
vaccin
short
notic
furthermor
need
develop
univers
influenza
vaccin
induc
broad
protect
immun
human
influenza
virus
potenti
pandem
virus
variou
subtyp
current
trival
inactiv
vaccin
commonli
use
protect
risk
group
season
influenza
viru
infect
vaccin
contain
compon
three
viru
strain
respons
epidem
outbreak
influenza
virus
influenza
b
viru
recent
quadrival
vaccin
becom
avail
contain
addit
antigen
differ
influenza
b
viru
compon
vaccin
aim
induct
virusneutr
antibodi
ha
na
order
vaccin
effect
great
import
vaccin
strain
antigen
match
epidem
strain
therefor
world
health
organ
make
recommend
vaccin
strain
twice
year
base
strain
like
circul
next
season
use
virus
whole
inactiv
vaccin
split
virion
vaccin
subunit
vaccin
prepar
addit
inactiv
influenza
vaccin
also
liveattenu
vaccin
avail
decad
use
season
influenza
vaccin
help
reduc
influenzarel
morbid
mortal
howev
prepar
use
current
inactiv
influenza
vaccin
limit
first
vaccin
strain
match
epidem
influenza
strain
antigen
vaccin
effect
reduc
addit
season
influenza
vaccin
offer
littl
protect
influenza
virus
novel
subtyp
pandem
potenti
second
vaccin
product
capac
even
manufactur
combin
limit
especi
case
pandem
outbreak
vaccin
need
becom
global
avail
short
period
time
third
take
long
vaccin
becom
avail
use
convent
product
method
exampl
pandem
outbreak
took
six
month
vaccin
campaign
start
countri
often
peak
pandem
fourth
subject
highrisk
group
may
respond
optim
vaccin
thu
vaccin
least
effect
peopl
need
final
inactiv
influenza
vaccin
ineffici
induc
virusspecif
cell
contribut
crossprotect
immun
limit
underscor
need
develop
novel
vaccin
product
platform
novel
vaccin
candid
allow
rapid
avail
vaccin
face
emerg
pandem
also
may
use
induct
broad
protect
immun
sever
approach
differ
stage
develop
investig
order
achiev
ultim
goal
univers
influenza
vaccin
describ
immunogen
potenti
differ
influenza
viru
antigen
assess
context
univers
influenza
vaccin
develop
antibodi
respons
induc
influenza
viru
infect
vaccin
mainli
direct
surfac
protein
ha
antibodi
neutral
activ
prevent
viru
attach
host
cell
post
attach
fusion
event
ha
consist
two
domain
globular
headdomain
highli
variabl
within
subtyp
conserv
stalkdomain
base
phylogenet
analysi
nucleotid
sequenc
ha
influenza
virus
divid
group
group
virus
broadli
neutral
antibodi
specif
headdomain
describ
howev
consid
high
mutat
rate
domain
elicit
antibodi
respons
specif
stalkdomain
potenti
induc
heterosubtyp
immun
ha
stalkspecif
antibodi
induc
influenza
viru
infect
vaccin
howev
magnitud
stalkspecif
antibodi
respons
vari
consider
individu
moreov
given
low
frequenc
stalkspecif
b
cell
unlik
antibodi
level
induc
upon
influenza
viru
infect
afford
protect
shown
passiv
immun
stalkspecif
antibodi
afford
protect
infect
heterolog
influenza
viru
mice
ferret
review
sever
ha
stalkbas
vaccin
strategi
describ
includ
sequenti
vaccin
chimer
ha
contain
conserv
stalk
headdomain
differ
influenza
subtyp
furthermor
modif
headdomain
introduct
extra
glycosyl
site
shield
headdomain
recognit
virusspecif
bcell
favor
antibodi
respons
stalkdomain
also
seem
promis
strategi
induc
robust
antistalk
antibodi
respons
howev
stalkreact
antibodi
specif
group
group
haexpress
influenza
virus
rare
therefor
univers
vaccin
induc
boost
stalkspecif
antibodi
respons
would
probabl
requir
compon
group
group
ha
protein
influenza
b
virus
second
surfac
protein
na
enabl
releas
progeni
virion
host
cell
surfac
upon
influenza
viru
infect
naspecif
antibodi
induc
boost
vaccin
trival
influenza
vaccin
naspecif
antibodi
abl
exert
heterosubtyp
immun
extent
ha
stalkspecif
antibodi
nevertheless
shown
antina
antibodi
provid
intrasubtyp
immun
contrast
ha
antibodi
prevent
viru
infect
rather
hamper
releas
newli
form
viru
particl
naspecif
antibodi
elicit
natur
infect
also
na
antibodi
induc
immun
provid
intrasubtyp
protect
vaccin
dna
plasmid
express
na
shown
provid
protect
infect
structur
similar
influenza
viru
given
narrow
rang
protect
naspecif
antibodi
respons
standalon
nabas
vaccin
would
attract
candid
univers
influenza
vaccin
develop
howev
addit
na
ha
compon
improv
virusspecif
antibodi
respons
third
minor
surfac
protein
matrix
protein
form
ion
channel
viral
envelop
specif
ectodomain
consid
good
candid
univers
influenza
vaccin
develop
rel
conserv
among
influenza
virus
antibodi
specif
unabl
neutral
viru
due
inabl
bind
protein
virion
surfac
howev
antibodi
bind
expos
surfac
infect
host
cell
antibodi
mediat
kill
infect
cell
antibodydepend
cellular
cytotox
adcc
like
natur
killer
nk
cell
antibodi
may
also
opson
infect
cell
phagocytosi
macrophag
due
poor
immunogen
vaccin
develop
base
protein
challeng
howev
vaccin
adjuv
robust
antibodi
respons
induc
sever
influenza
vaccin
candid
describ
valid
variou
anim
model
includ
dna
construct
viruslik
particl
vlp
viral
vector
shown
vaccin
provid
protect
infect
heterolog
viru
moreov
even
six
month
vaccin
mice
protect
homolog
challeng
infect
indic
vaccin
provid
longterm
protect
current
vaccin
test
clinic
trial
howev
antibodi
alon
provid
steril
immun
therefor
combin
anoth
influenza
antigen
might
induc
better
protect
immun
respons
influenza
viru
infect
antigen
present
cell
apc
predominantli
dendrit
cell
dc
process
viral
protein
peptid
present
cell
upon
recognit
peptid
bound
major
histocompat
complex
mhc
clonal
expans
virusspecif
cell
effector
cell
second
signal
costimulatori
molecul
requir
prevent
abort
clonal
expans
activ
cell
migrat
lung
recogn
elimin
infect
epitheli
cell
infect
clear
two
type
memori
cell
establish
long
live
central
memori
cell
effector
memori
cell
alreadi
recogn
year
ago
conserv
intern
influenza
viru
protein
like
nucleoprotein
np
matrix
protein
target
cytotox
lymphocyt
ctl
consequ
crossreact
influenza
virus
differ
subtyp
infect
season
influenza
viru
induc
ctl
even
crossreact
influenza
virus
avian
swine
origin
gener
accept
virusspecif
cell
play
import
role
crossprotect
immun
recent
demonstr
anim
model
human
also
helper
cell
contribut
crossprotect
immun
upon
infect
heterolog
influenza
virus
crossreact
anamnest
cell
respons
contribut
acceler
clearanc
infect
reduct
clinic
symptom
influenza
vaccin
aim
induct
virusspecif
cell
mainli
target
intern
protein
np
deliv
protein
peptidecarri
conjug
vlp
dna
plasmid
viral
vector
howev
also
rel
conserv
influenza
viru
protein
might
consid
induct
crossreact
cell
respons
like
polymeras
subunit
pa
describ
sever
promis
target
develop
univers
influenza
vaccin
sever
vaccin
strategi
evalu
given
virusspecif
antibodi
also
cell
contribut
cross
protect
immun
import
univers
influenza
vaccin
activ
arm
adapt
immun
system
respect
use
viral
vector
deliveri
viral
protein
advantag
convent
vaccin
hold
promis
overexpress
viral
protein
potenti
increas
immunogen
furthermor
use
live
vector
allow
de
novo
synthesi
viral
protein
cytosol
antigen
present
cell
thu
facilit
antigen
process
present
virusspecif
cell
altern
crossprim
may
result
activ
cell
thu
vector
vaccin
may
induc
virusspecif
antibodi
respons
also
induc
cellmedi
immun
respons
moreov
antigen
interest
express
nativ
conform
thu
induc
antibodi
proper
specif
last
least
viral
vector
vaccin
design
produc
rapidli
use
largescal
vaccin
product
make
attract
vaccin
candid
face
emerg
pandem
outbreak
variou
vector
test
context
viral
vector
vaccin
modifi
vaccinia
viru
ankara
mva
discuss
review
adenoviru
vector
promin
candid
modifi
vaccinia
viru
ankara
mva
deriv
chorioallantoi
vaccinia
viru
ankara
cva
serial
passag
chicken
embryo
fibroblast
cef
bavarian
state
vaccin
institut
produc
mva
human
smallpox
vaccin
applic
mva
vaccin
success
increas
safeti
convent
smallpox
vaccin
document
absenc
seriou
advers
event
larg
field
trial
involv
individu
germani
serial
passag
mva
primari
secondari
cef
cultur
result
major
delet
viral
genom
mani
mutat
affect
known
vaccinia
viru
vacv
virul
immun
evas
factor
consequ
mva
replic
highli
restrict
avian
cell
viru
unabl
produc
infecti
progeni
cell
mammalian
origin
host
cell
restrict
mva
associ
late
block
assembl
viral
particl
nonpermiss
cell
phenotyp
rather
except
among
poxvirus
host
rang
defici
usual
block
prior
stage
abort
infect
mammalian
cell
nonrepl
mva
allow
unimpair
synthesi
viral
earli
intermedi
abund
late
gene
product
support
develop
safe
particularli
effici
viral
vector
moreov
biolog
safeti
replic
defici
mva
confirm
variou
vivo
model
includ
avian
speci
anim
sever
immunodefici
therefor
recombin
mva
virus
genet
modifi
organ
use
condit
biosafeti
level
countri
provid
innocu
heterolog
gene
sequenc
express
latter
attribut
import
advantag
compar
replic
compet
poxviru
vector
bsl
organ
viral
vector
certainli
contribut
increas
use
recombin
mva
clinic
test
deliv
heterolog
antigen
mva
vector
vaccin
target
gene
sequenc
transcrib
highli
specif
control
poxvir
promot
recogn
activ
viru
encod
enzym
transcript
factor
recombin
gene
transient
express
infect
nonrepl
mva
sinc
surviv
mva
infect
host
cell
assum
full
clearanc
recombin
viru
recombin
dna
occur
within
day
vaccin
administr
despit
transient
product
heterolog
protein
mva
vector
vaccin
abl
elicit
high
level
antigenspecif
humor
cellular
immun
respons
demonstr
first
mva
candid
vaccin
deliv
influenza
antigen
review
see
note
even
activ
antigenspecif
cell
respons
deliveri
stabl
protein
might
advantag
compar
immunogen
design
rapid
intracellular
degrad
seem
suggest
mvadeliv
protein
effici
present
via
endogen
crosspresent
pathway
mhc
class
antigen
process
review
see
anoth
characterist
mva
vaccin
surpris
level
immunogen
protect
capac
compar
replic
vacv
vector
vaccin
express
recombin
gene
replic
compet
vector
capac
amplifi
vivo
could
expect
infect
target
cell
produc
higher
amount
antigen
per
immun
nonrepl
mva
vector
nevertheless
efficaci
mva
vaccin
compar
favor
outcom
immun
replic
compet
vacv
vector
mice
nonhuman
primat
observ
may
best
explain
capac
mva
readili
activ
variou
compon
host
innat
immun
system
probabl
lack
mani
immun
evas
factor
encod
wildtyp
vacv
thu
unlik
vacv
strain
mva
produc
solubl
viru
protein
function
receptorlik
inhibitor
type
type
ii
interferon
tumor
necrosi
factor
chemokin
moreov
mva
infect
sens
multipl
intracellular
host
detect
mechan
result
product
interferon
inflammatori
cytokin
chemokin
noteworthi
mva
lost
sever
vacv
inhibitor
target
intracellular
signal
pathway
eg
host
activ
consequ
vivo
infect
mva
vacv
strain
trigger
rapid
immigr
monocyt
neutrophil
lymphocyt
site
inocul
intrins
immunostimul
activ
suggest
use
addit
adjuv
system
togeth
mva
might
dispens
vaccin
applic
final
continu
advanc
genet
engin
process
develop
largescal
manufactur
mvaspecif
immun
monitor
brought
recombin
mva
clinic
trial
increas
scale
success
develop
mvabas
next
gener
vaccin
smallpox
licens
europ
canada
also
contribut
substanti
groundwork
develop
futur
recombin
mva
vaccin
indic
mva
hold
great
promis
viral
vaccin
vector
test
candid
vaccin
influenza
sever
studi
result
studi
summar
tabl
suggest
efficaci
vector
vaccin
could
hamper
preexist
immun
vector
howev
demonstr
mva
issu
sinc
mva
protect
immun
could
induc
influenza
presenc
preexist
vector
immun
highli
pathogen
avian
influenza
virus
subtyp
caus
mainli
endem
outbreak
poultri
sinc
first
human
case
infect
avian
influenza
viru
case
report
fatal
outcom
circul
virus
poultri
sever
geograph
region
continu
pose
threat
public
health
pandem
outbreak
viru
still
fear
sinc
demonstr
hand
mutat
suffici
virus
becom
transmiss
mammal
develop
efficaci
vaccin
complic
cocircul
virus
belong
variou
antigen
distinct
clade
ideal
novel
vaccin
induc
antibodi
crossreact
virus
multipl
clade
sever
recombin
mva
vaccin
express
ha
gene
variou
virus
construct
test
variou
anim
model
mva
express
ha
gene
influenza
viru
strain
induc
strong
antibodi
respons
crossreact
virus
extent
protect
mice
infect
homolog
heterolog
virus
induc
superior
protect
immun
mice
homolog
heterolog
virus
compar
mva
express
ha
gene
virus
ahong
also
test
nonhuman
primat
two
immun
pfu
protect
cynomolgu
macaqu
infect
influenza
virus
also
prove
immunogen
chicken
afford
protect
infect
favor
outcom
preclin
test
prompt
clinic
test
vaccin
candid
ongo
phase
iii
trial
assess
whether
protect
immun
also
could
achiev
lower
dose
mva
dose
find
perform
mice
interestingli
two
immun
dose
low
pfu
suffici
induc
protect
immun
infect
homolog
heterolog
virus
howev
dose
pfu
requir
induct
steril
immun
homolog
strain
furthermor
singl
immun
dose
rang
pfu
result
protect
diseas
albeit
steril
immun
achiev
data
indic
case
pandem
larg
number
vaccin
dose
need
produc
short
period
time
protect
immun
virus
induc
one
two
low
dose
mva
order
evalu
mvabas
vaccin
viru
caus
pandem
ha
gene
prototyp
strain
clone
mva
mice
vaccin
protect
infect
pandem
influenza
viru
protect
correl
induct
viru
neutral
antibodi
virusspecif
cell
addit
crossprotect
immun
swine
influenza
virus
induc
thu
vaccin
induc
extent
intrasubtyp
immun
mice
vaccin
also
test
ferret
one
immun
afford
modest
protect
second
immun
induc
robust
antibodi
titer
reduc
viru
replic
challeng
infect
influenza
viru
howev
full
steril
immun
achiev
may
relat
rout
administr
andor
dose
challeng
viru
taken
togeth
data
indic
mvabas
vaccin
would
abl
induc
protect
immun
viru
caus
pandem
although
extent
crossprotect
unrel
virus
may
limit
order
elicit
virusspecif
antibodi
cell
respons
singl
vaccin
recombin
mva
express
ha
np
gene
construct
mva
express
np
ha
gene
deriv
influenza
viru
apuerto
induc
protect
antibodi
ctl
respons
homolog
heterolog
infect
mice
mvahanp
vaccin
prepar
ha
gene
obtain
use
induc
crossprotect
immun
infect
homolog
pandem
strain
unrel
strain
influenza
viru
furthermor
vaccin
afford
partial
protect
challeng
influenza
virus
thu
recombin
mva
express
ha
gene
viru
highli
conserv
np
gene
induc
heterosubtyp
immun
contrast
induc
protect
viru
pandem
strain
design
mvabas
vaccin
aim
induct
virusspecif
cell
respons
recombin
mva
construct
express
gene
encod
rel
conserv
intern
structur
protein
np
vaccin
test
phase
phase
iia
clinic
trial
vaccin
induc
mainli
virusspecif
cell
detect
one
week
intramuscular
immun
induc
protect
immun
experiment
infect
one
month
vaccin
vaccin
test
healthi
adult
year
age
also
peopl
year
age
shown
vaccin
could
safe
administ
elderli
differ
vaccin
strategi
investig
seem
prime
adenoviru
vector
express
np
subsequ
boost
mva
express
antigen
induc
higher
level
protect
cell
vaccin
either
vector
alon
strongest
cell
respons
obtain
intramuscular
administr
adenoviru
vector
intranas
intramuscular
administr
mva
compar
intraderm
inject
intramuscular
immun
prefer
vaccin
easi
administ
optim
balanc
immunogen
side
effect
addit
combin
prime
boost
hacontain
compon
test
sinc
mva
potenti
second
immun
prime
boost
trival
influenza
vaccin
result
higher
level
total
igg
affect
number
ifnyproduc
cell
compar
vaccin
mva
alon
combin
vaccin
strategi
protect
mice
heterolog
challeng
infect
six
month
immun
order
develop
univers
influenza
vaccin
variou
recombin
mva
express
varieti
conserv
antigen
deriv
influenza
viru
construct
antigen
includ
np
ha
stalkdomain
hastalk
combin
np
hastalk
combin
four
repeat
deriv
virus
mice
immun
twice
respect
mva
vaccin
subsequ
infect
influenza
viru
subtyp
pandem
potenti
mous
adapt
mva
express
np
hastalknp
induc
heterosubtyp
immun
coexpress
np
seem
essenti
sinc
express
np
induc
viru
specif
cell
mva
vaccin
test
mvahastalk
fail
induc
protect
immun
interestingli
vaccin
predispos
sever
diseas
upon
challeng
infect
mice
although
differ
surviv
rate
control
group
statist
signific
thu
mva
wide
use
develop
influenza
vaccin
show
encourag
result
vector
hold
great
promis
vaccin
platform
respiratori
virus
gener
combin
adenoviru
vaccin
protect
antibodi
respons
cell
respons
measur
import
virus
paramyxovirida
famili
includ
human
parainfluenza
virus
piv
human
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
pathogen
transmit
via
respiratori
rout
caus
agent
acut
respiratori
tract
infect
human
particularli
young
children
elderli
immunocompromis
infect
virus
among
lead
reason
pediatr
hospit
review
see
present
licens
vaccin
effect
prevent
infect
spur
evalu
first
recombin
mva
vaccin
piv
rsv
recombin
mva
coproduc
fusion
f
hemagglutininneuramidas
hn
protein
gener
preclin
test
anim
model
cotton
rat
model
recombin
mva
elicit
high
level
pivspecif
antibodi
upon
immun
intramuscular
intranas
applic
upon
challeng
mvahn
effici
induc
protect
determin
substanti
reduct
piv
load
nasal
turbin
lung
result
favor
compar
respons
achiev
attenu
live
piv
candid
vaccin
furthermor
use
rhesu
macaqu
recombin
mva
vaccin
also
induc
protect
piv
challeng
although
intranas
vaccin
could
complet
prevent
infect
upper
respiratori
tract
first
gener
candid
mva
vaccin
rsv
express
recombin
gene
sequenc
encod
either
rsv
fusion
protein
f
glycoprotein
g
envelop
antigen
togeth
mice
recombin
mva
induc
rsvspecif
antibodi
level
mva
vaccin
induc
circul
antibodi
even
higher
found
experiment
rsv
infect
followup
studi
mva
vector
mous
model
also
demonstr
induct
strong
rsvspecif
cell
respons
result
clearanc
rsv
lung
vaccin
anim
although
also
associ
weightloss
vaccin
anim
enhanc
rsvmediat
lung
eosinophilia
seen
upon
challeng
infect
mva
vector
vaccin
anim
parallel
immun
studi
infant
cynomolgu
macaqu
also
suggest
vaccin
recombin
mva
predispos
rsv
associ
immunopatholog
howev
combin
intramuscularintranas
immun
infant
year
old
macaqu
recombin
mva
fail
provid
protect
rsv
replic
lower
respiratori
tract
evalu
safeti
efficaci
new
approach
rsv
vaccin
develop
infect
cattl
bovin
rsv
brsv
provid
excel
altern
model
use
highli
relat
pathogen
natur
host
recombin
mva
deliv
brsv
f
g
glycoprotein
antigen
mvabrsv
test
protect
calv
brsv
challeng
intramuscular
vaccin
calv
mvabrsv
induc
brsv
specif
igg
antibodi
cell
respons
detect
ige
antibodi
upon
challeng
brsv
mvabrsv
vaccin
calv
compar
control
anim
demonstr
less
sever
lower
respiratori
tract
symptom
reduc
pulmonari
viru
load
sign
brsvassoci
immunopatholog
eosinophil
infiltr
howev
complet
protect
brsv
infect
replic
achiev
overal
previou
studi
suggest
safeti
least
partial
efficaci
first
gener
recombin
mva
vaccin
piv
rsv
applic
recombin
mva
includ
mucos
deliveri
use
primeboost
strategi
may
contribut
improv
effect
prevent
immun
respiratori
diseas
last
decad
two
new
beta
coronavirus
transmit
anim
reservoir
probabl
bat
speci
human
caus
major
acut
respiratori
diseas
associ
high
mortal
rate
sever
acut
respiratori
syndrom
coronaviru
sarscov
recent
middl
east
respiratori
syndrom
coronaviru
merscov
review
see
present
vaccin
avail
approv
emerg
use
human
prevent
either
sarscov
merscov
infect
one
year
recognit
sarscov
human
recombin
mva
express
spike
protein
consid
key
compon
coronavirusspecif
vaccin
gener
demonstr
elicit
viru
neutral
antibodi
mice
also
anoth
recombin
mva
vaccin
produc
sarscov
antigen
found
induc
high
level
neutral
antibodi
respons
mice
rabbit
rhesu
macaqu
moreov
monkey
model
two
immun
recombin
mva
prevent
replic
sarscov
upon
respiratori
challeng
infect
similarli
within
year
appear
merscov
first
candid
mva
vector
vaccin
produc
glycoprotein
merscov
mvamerss
obtain
balbc
mice
intramuscularli
im
vaccin
pfu
mvamerss
singl
administr
mvamerss
vaccin
alreadi
induc
low
level
virusneutr
antibodi
anim
test
booster
immun
vaccin
anim
produc
high
level
circul
antibodi
neutral
merscov
contrast
neutral
antibodi
detect
sera
control
anim
specif
induc
respons
confirm
absenc
detect
neutral
sarscov
data
support
evalu
mvamerss
candid
emerg
vaccin
gener
swift
applic
recombin
mva
respons
appear
sarscov
merscov
demonstr
suitabl
vector
system
readili
respond
potenti
threat
suddenli
emerg
infecti
diseas
mva
great
potenti
rapid
respons
vaccin
platform
newli
emerg
viru
infect
establish
standard
protocol
allow
rapidli
obtain
recombin
mva
rmva
suitabl
clinic
evalu
review
see
done
infect
cef
fulli
character
nonrecombin
mva
seed
viru
subsequ
transfect
vector
plasmid
dna
contain
target
gene
interest
homolog
recombin
heterolog
gene
sequenc
insert
viral
genom
rmva
clonal
select
amplifi
serial
passag
cef
deriv
certifi
embryon
egg
specif
pathogen
free
spf
chicken
ideal
process
human
case
infect
novel
respiratori
viru
construct
isol
candid
rmva
take
week
figur
order
produc
enough
vaccin
dose
largescal
immun
campaign
larg
bulk
tissu
cultur
requir
use
cef
well
establish
vaccin
manufactur
primari
cef
readili
prepar
embryon
egg
without
need
amplif
known
product
season
influenza
vaccin
million
egg
obtain
handl
within
day
cef
produc
larg
scale
cryopreserv
later
time
point
howev
cryopreserv
impact
qualiti
cell
therefor
especi
context
pandem
prepared
continu
cell
line
allow
effici
mva
propag
duck
cell
line
would
benefici
gener
rmva
vector
vaccin
need
valid
vitro
verifi
genet
stabil
antigen
express
unimpair
growth
capac
subsequ
vivo
experi
preclin
model
eg
mice
ferret
andor
macaqu
perform
determin
immunogen
usual
test
variou
dosag
rout
administr
possibl
obtain
efficaci
data
success
preclin
phase
vaccin
readi
test
human
far
mvabas
vaccin
regist
market
human
use
numer
vaccin
test
clinic
trial
phase
clinic
trial
safeti
vaccin
administr
test
phase
ii
safeti
efficaci
assess
often
involv
variou
studi
popul
phase
iii
safeti
efficaci
confirm
larg
studi
group
vaccin
success
differ
phase
clinic
trial
regist
common
use
figur
howev
pitfal
develop
novel
recombin
mva
vaccin
might
take
preciou
time
verg
pandem
first
take
time
develop
suitabl
anim
model
newli
emerg
respiratori
infect
second
new
vaccin
antigen
potenc
puriti
assay
need
develop
appropri
qualiti
assess
mva
vaccin
prepar
third
new
rmva
viru
new
biolog
entiti
therefor
new
vaccin
must
test
thoroughli
howev
case
sever
pandem
would
like
time
go
phase
clinic
trial
furthermor
combin
vaccin
strategi
eg
prime
adenoviru
vector
boost
mva
vaccin
lead
complic
regulatori
procedur
two
distinct
biolog
entiti
need
approv
fourth
even
though
handson
develop
work
done
rapidli
nonclin
safeti
test
eg
toxic
studi
ethic
approv
anim
experi
clinic
trial
registr
vaccin
alway
depend
extern
parti
could
substanti
slow
develop
final
also
immun
vector
eg
preexist
smallpox
vaccin
need
consid
howev
studi
shown
even
multipl
immun
rmva
still
abl
induc
foreign
antigenspecif
immun
respons
presenc
mvaspecif
antibodi
test
vitro
assess
correct
gene
insert
protein
express
rmva
infect
cell
eg
western
blot
flow
cytometri
subsequ
vaccin
immunogen
efficaci
test
mice
ferret
andor
macaqu
mvabas
vaccin
success
preclin
test
vaccin
test
phase
ii
iii
clinic
trail
final
vaccin
proven
safe
effect
file
market
author
addit
practic
issu
regulatori
issu
need
address
far
one
guidelin
qualiti
non
clinic
aspect
live
recombin
viral
vector
exist
case
influenza
special
procedur
place
european
union
speed
author
process
novel
vaccin
case
pandem
vaccin
need
becom
avail
soon
possibl
normal
procedur
approv
new
vaccin
take
month
obvious
long
novel
vaccin
case
influenza
pandem
therefor
two
procedur
place
author
pandem
influenza
vaccin
first
one
mockup
procedur
prototyp
vaccin
author
possibl
predict
strain
caus
pandem
therefor
vaccin
base
strain
potenti
induc
pandem
develop
test
proofofprincipl
vaccin
regist
viral
strain
actual
caus
pandem
identifi
includ
mockup
vaccin
approv
quickli
second
emerg
procedur
allow
fasttrack
approv
vaccin
pandem
alreadi
start
emerg
procedur
vaccin
approv
day
mva
vectorbas
vaccin
cover
pandem
influenza
vaccin
registr
procedur
even
though
mvabas
vaccin
develop
produc
rel
quickli
pandem
outbreak
vaccin
avail
time
prevent
widespread
pandem
describ
recombin
mva
mani
featur
serv
excel
platform
product
emerg
vaccin
vector
vaccin
foreign
antigen
encod
express
nativ
conform
authent
process
present
immun
system
allow
induct
balanc
humor
cellular
respons
induc
solid
pathogenspecif
immun
addit
mvaspecif
benefit
mva
extrem
replicationdefici
mammalian
host
cell
mediat
strictli
transient
express
heterolog
target
gene
viru
highli
attenu
vivo
model
test
therefor
rmva
vaccin
excel
safeti
profil
consid
clinic
use
protect
gener
environ
furthermor
impact
preexist
vector
immun
limit
especi
compar
viral
vector
adenovirusbas
vaccin
final
rmva
vaccin
expect
stabl
time
enabl
shipment
applic
remot
area
limit
coldchain
mainten
even
though
mvabas
emerg
vaccin
develop
rel
quickli
still
hurdl
overcom
practic
issu
well
regulatori
issu
need
address
order
develop
platform
optim
use
pandem
influenza
newli
emerg
respiratori
viru
infect
